Stonebridge Capital Advisors’s AstraZeneca AZN Stock Holding History

Stonebridge Capital Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-27	Closed	-$3.79K	–	930
2023 Q2	$3.79K	Sell	27 -287	-91%	-$42.2K	﹤0.01%	748
2023 Q1	$43.6K	Buy	314 +26	+9%	+$3.5K	0.01%	385
2022 Q4	$39K	Buy	288 +121	+72%	+$15.2K	﹤0.01%	388
2022 Q3	$18K	Buy	167 +14	+9%	+$1.78K	﹤0.01%	486
2022 Q2	$20K	Sell	153 -68	-31%	-$8.92K	﹤0.01%	489
2022 Q1	$29K	Hold	221	–	–	﹤0.01%	472
2021 Q4	$26K	Sell	221 -20	-8%	-$2.35K	﹤0.01%	466
2021 Q3	$29K	Buy	241 +20	+9%	+$2.33K	﹤0.01%	423
2021 Q2	$26K	Buy	221 +57	+35%	+$6.25K	﹤0.01%	447
2021 Q1	$16K	Buy	+164	New	+$16.5K	﹤0.01%	540
2020 Q3	–	Sell	-181	Closed	-$19K	–	224
2020 Q2	$19K	Hold	181	–	–	﹤0.01%	404
2020 Q1	$16K	Sell	181 -242	-57%	-$22.8K	﹤0.01%	413
2019 Q4	$42K	Buy	423 +227	+116%	+$21.4K	0.01%	341
2019 Q3	$17K	Hold	196	–	–	﹤0.01%	472
2019 Q2	$16K	Buy	+196	New	+$15.4K	﹤0.01%	495

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Stonebridge Capital Advisors's AZN Position: Q3 2023 in Review

Stonebridge Capital Advisors sold out of AstraZeneca (AZN) in Q3 2023, closing a stake of 27 shares — an estimated $3.79K sold.

Stonebridge Capital Advisors first reported a position in AZN in Q2 2019 and held it in 15 quarters. The position peaked at $43.6K in Q1 2023. 1,073 funds tracked by Wall St. Rank hold AZN as of Q3 2023.

Stonebridge Capital Advisors reported no remaining AstraZeneca position as of Q3 2023 after selling out during the quarter.
Stonebridge Capital Advisors sold 27 AstraZeneca shares in Q3 2023, an estimated $3.79K.
Stonebridge Capital Advisors first reported a position in AstraZeneca in Q2 2019 and held it in 15 quarters.
Stonebridge Capital Advisors's AstraZeneca position peaked at $43.6K in Q1 2023.
1,073 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2023.

Based on Stonebridge Capital Advisors's 13F filing for Q3 2023, filed 15 Nov 2023.